SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - -------------------------------------------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2000 (March 28, 2000) Regeneron Pharmaceuticals, Inc. - -------------------------------------------------------------- (Exact name of registrant as specified in its charter) New York 333-31764 133444607 ------------ --------- ---------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No. incorporation) 777 Old Saw Mill River Rd, Tarrytown NY, 10591-6707 -------------------------------------------------------- (Address of principal executive offices) (Zip Code) 9143477000 - ---------------------------------------------------------------- (Registrant's telephone number, including area code) Regeneron Pharmaceuticals, Inc. Current Report on Form 8-K Item 5. Other Events On March 28, 2000, the registrant issued a press release announcing that it has initiated a Phase II dose ranging trial to study the safety and efficacy of AXOKINE second generation ciliary neurotrophic factor in obese patients. Item 7. Financial Statements and Exhibits. a. Financial Statements Not required b. Pro forma Financial Information Not required c. Exhibits Exhibit No. Description ----------- ---------- 99.01 Press Release of Regeneron Pharmaceuticals, Inc. dated March 28, 2000. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned's duly authorized signatory. Dated: March 29, 2000 REGENERON PHARMACEUTICALS, INC. By: /s/ Murray A. Goldberg ------------------------ Name: Murray A. Goldberg Title: Vice President, Finance & Administration, Chief Financial Officer, Treasurer and Assistant Secretary EXHIBIT INDEX Exhibit No. Description - ----------- ----------- 99.01 Press Release of Regeneron Pharmaceutical, Inc. dated March 28, 2000.